Coronary Artery DiseaseComparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes
Section snippets
Methods
A prospective, monocenter, open-label randomized study was performed from January 2014 to September 2014. Patients between 18 and 75 years old who underwent PCI for an intermediate or high-risk NSTE-ACS and agreeing to participate in the study were eligible. The present study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. All patients gave an informed consent.
They were randomized
Results
The present study included 213 patients: 106 in the ticagrelor group and 107 in the prasugrel group. The 2 groups were similar in terms of baseline characteristics as summarized in Table 1. In particular, the rate of non–ST-elevation myocardial infarction as defined by a preprocedural troponin Ic more than the ninety-ninth percentiles was similar between the 2 groups (ticagrelor vs prasugrel: 53.8% vs 45.8%; p = 0.2).
The main angiographic and interventional characteristics are depicted in
Discussion
The present study demonstrated that pretreatment with a ticagrelor LD before PCI significantly reduced the occurrence of periprocedural myonecrosis in patients with NSTE-ACS who underwent PCI compared with prasugrel given at the time of PCI. Because periprocedural myonecrosis have been associated with short- and long-term clinical outcome, the present pilot study supports pretreatment with ticagrelor in intermediate and high-risk NSTE-ACS to improve the outcome.
Platelet-rich thrombus plays a
Disclosures
The present study was supported by a grant from the Assistance Publique—Hopitaux de Marseille (grant number 251929). Dr. Bonello received lecture fees from Sanofi (Paris, France), Eli Lilly (Indianapolis), and AstraZeneca (Londres) and Medicine Company (Parsippany) and research grant from Astrazeneca; Dr. Laine received lectures fee from Astrazeneca; and Dr. Paganelli received lecture fees from Sanofi, Eli Lilly, and AstraZeneca and research grant from Astrazeneca. None of the authors have
References (21)
- et al.
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study
J Am Coll Cardiol
(2013) - et al.
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention
JACC Cardiovasc Interv
(2010) - et al.
Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality
J Am Coll Cardiol
(2006) - et al.
Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention
Int J Cardiol
(2003) - et al.
Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes
Am J Cardiol
(2009) - et al.
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends
J Am Coll Cardiol
(2013) - et al.
Third universal definition of myocardial infarction
J Am Coll Cardiol
(2012) - et al.
Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
Lancet
(2001) - et al.
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study
JACC Cardiovasc Interv
(2008) - et al.
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome
J Am Coll Cardiol
(2014)
Cited by (30)
Timing, Selection, Modulation, and Duration of P2Y<inf>12</inf> Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI
2023, JACC: Cardiovascular InterventionsPrasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
2020, Cardiovascular Revascularization MedicineCitation Excerpt :The cumulative Z-curve did not exceed the traditional boundary for statistical significance; thus, the result is inconclusive (Supplemental Figs. 4). In our meta-analysis of available trials [12–17] (6 RCTs, 6807 participants) comparing prasugrel and ticagrelor, there was no significant difference in MACE, cardiovascular mortality, all-cause mortality, MI, stent thrombosis, major bleeding, and all bleeding. A very large study would be required to reach a conclusive result.
Ticagrelor or Prasugrel in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
2020, Journal of the American College of CardiologyCitation Excerpt :In the ACCOAST (Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pre-treatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction) trial that comprised patients with NSTE-ACS, pre-treatment with prasugrel before coronary anatomy was known did not reduce the risk of ischemic events compared with treatment in the catheterization laboratory, but increased the risk of bleeding substantially (10). A randomized study in 213 patients with NSTE-ACS comparing loading with ticagrelor as soon as possible after admission with prasugrel given at the time of PCI suggested a possible protection against peri-procedural myonecrosis by ticagrelor pre-treatment (19). In the ATLANTIC (Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST-Elevation Myocardial Infarction to Open the Coronary Artery) trial, pre-treatment with ticagrelor did not improve resolution of ST-segment elevation before PCI or Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 in the infarct-related artery (20).
Meta-Analysis Comparing the Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome
2020, American Journal of CardiologyTicagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis
2018, Journal of the Neurological SciencesCitation Excerpt :Five RCTs were conducted in China, one each in Japan, France and Czech Republic, whereas remaining were multinational trials. The control group consisted of clopidogrel in 8 RCTs [1,3,15,16,18–22], prasugrel in 2 RCTs [17,23], aspirin in one RCT [4], and placebo in one RCT [2]. The individual and pooled assessments of the risk of bias across included studies are presented in Supplemental Fig. II.
Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies
2017, International Journal of CardiologyCitation Excerpt :Finally, we had a total of 9 publications for qualitative and quantitative analysis. Four studies were randomized trials [17,19,24,25] and five were observational [16,18,26–28]. The individual study characteristics, patient characteristics and inclusion/exclusion criteria of the included studies are shown respectively in Table 1, Table 2, and E-Table 3.
See page 342 for disclosure information.